Lamivudine
PubChem CID: 60825
Connections displayed (default: 10).
Loading graph...
| Compound Synonyms | lamivudine, 134678-17-4, Epivir, Zeffix, Heptovir, Epivir-HBV, Hepitec, 136891-12-8, 2',3'-Dideoxy-3'-thiacytidine, BCH-189, 3TC, Heptodin, (-)-2'-Deoxy-3'-thiacytidine, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, GR-109714X, VIROLAM, GR109714X, 3'-Thia-2',3'-dideoxycytidine, Lamivudine teva, beta-L-2',3'-Dideoxy-3'-thiacytidine, beta-L-3'-Thia-2',3'-dideoxycytidine, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one, GR 109714X, (-)-BCH-189, (-)NGPB-21, Epivir (TN), BCH 189, (-)-, Lamivudina, Lamivudinum, BCH189, (-)-BCH 189, HSDB 7155, 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE, 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE, (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine, CCRIS 9274, CHEBI:63577, Lamivudine [USAN:USP:INN:BAN], LAMIVUDINE [MI], 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one, LAMIVUDINE [INN], LAMIVUDINE [JAN], LAMIVUDINE [HSDB], LAMIVUDINE [USAN], MFCD00869739, LAMIVUDINE [VANDF], 2T8Q726O95, NSC-760061, LAMIVUDINE [MART.], CIS-LAMIVUDINE, LAMIVUDINE [USP-RS], LAMIVUDINE [WHO-DD], LAMIVUDINE [WHO-IP], LAMIVUDINE [EMA EPAR], 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-, DTXSID7023194, LAMIVUDINE [EP IMPURITY], LAMIVUDINE [ORANGE BOOK], LAMIVUDINE [EP MONOGRAPH], KIVEXA COMPONENT LAMIVUDINE, LAMIVUDINE [USP MONOGRAPH], (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, EPZICOM COMPONENT LAMIVUDINE, TEMIXYS COMPONENT LAMIVUDINE, TRIUMEQ COMPONENT LAMIVUDINE, LAMIVUDINUM [WHO-IP LATIN], COMBIVIR COMPONENT LAMIVUDINE, LAMIVUDINE TEVA PHARMA B.V., TRIZIVIR COMPONENT LAMIVUDINE, 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, DELSTRIGO COMPONENT LAMIVUDINE, NSC 760061, EMTRICITABINE IMPURITY C [WHO-IP], Heptivir, Lamivir, Zefix, BCH 189, LAMIVUDINE (MART.), LAMIVUDINE (USP-RS), LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE, LAMIVUDINE (EP IMPURITY), LAMIVUDINE (EP MONOGRAPH), Lamivudine [USAN:BAN:INN], LAMIVUDINE (USP MONOGRAPH), Lamivudine (USAN:USP:INN:BAN), (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine, 3TC Lamivudine, Epivir HBV, 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, Lamivudine, 3TC, Epivir(TM), 4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP], HHA & Lamivudine, Lamivudine & GNA, SMR000466319, DTHC, CHEMBL141, 2',3' Dideoxy 3' thiacytidine, DRG-0126, 3TC and NV-01, 3TC, 2',3'-Dideoxy-3'-thiacytidine, (-)-BCH-189, (-)-SddC, Lamivudine (JAN/USP/INN), 1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine, 1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, 3TC & GNA, 3TC & SST, HHA & 3TC, lamivudine oral, (+/-)-SddC, NSC620753, UNII-2T8Q726O95, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-1,2-dihydropyrimidin-2-one, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2-one, BCH-790, NCGC00159341-04, GG-714, MFCD00870542, Lamivudine (Standard), Lamivudine (EPIVIR), CPD000466319, (+/-)-3TC, (+/-)-BCH-189, (2R-cis)-4-Amino-1-, MLS000759424, MLS001424097, MLS006011910, BIDD:GT0033, SCHEMBL109675, EMTRICITABINE IMPURITY C, Lamivudine - Bio-X trade mark, GTPL12673, HY-B0250R, J05AF05, DTXCID001508532, HMS2051D21, HMS3259F08, HMS3713C16, HY-B0250, BBL033871, BDBM50366817, s1706, STK801940, lamivudine & TNF-alpha & IFN-gamma, TELURA COMPONENT OF LAMIVUDINE, AKOS005622556, AKOS015854841, LAMIVUDINE COMPONENT OF EPZICOM, LAMIVUDINE COMPONENT OF TEMIXYS, LAMIVUDINE COMPONENT OF TRIUMEQ, Lamivudine, >=98% (HPLC), powder, (-)-BCH189, AC-1416, CCG-100984, DB00709, KS-1073, LAMIVUDINE COMPONENT OF COMBIVIR, LAMIVUDINE COMPONENT OF DUTREBIS, LAMIVUDINE COMPONENT OF TRIZIVIR, NC00234, NC00705, NL06295, LAMIVUDINE COMPONENT OF DELSTRIGO, NCGC00159341-05, NCGC00159341-18, NCGC00159341-20, BL164607, L0217, NS00007004, rac-cis-Lamivudine ((2RS,5SR)-Lamivudine), SW197614-3, C07065, D00353, EN300-123034, Lamivudine 100 microg/mL in Acetonitrile:Water, P17147, AB00639995-06, AB00639995-08, AB00639995_09, Q422631, SR-01000759420, SR-01000759420-5, BRD-K02992638-001-11-8, LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA, Z1509637175, Lamivudine, British Pharmacopoeia (BP) Reference Standard, Lamivudine, European Pharmacopoeia (EP) Reference Standard, (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To, Lamivudine, United States Pharmacopeia (USP) Reference Standard, (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE, LAMIVUDINE, EPIVIR, Lamivudine, 1.0 mg/mL in methanol, certified reference material, Lamivudine, Pharmaceutical Secondary Standard, Certified Reference Material, (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis), 2(1H)-Pyrimidinone,4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one, cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone, Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard, Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard, 1117764-41-6, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA), 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA), 603-844-3 |
|---|---|
| Topological Polar Surface Area | 113.0 |
| Hydrogen Bond Donor Count | 2.0 |
| Heavy Atom Count | 15.0 |
| Isotope Atom Count | 0.0 |
| Molecular Complexity | 331.0 |
| Database Name | cmaup_ingredients;npass_chem_all;pubchem |
| Defined Atom Stereocenter Count | 2.0 |
| Uniprot Id | n.a., Q72547, Q72874, P02545, P38532, P10636, O60840, P02768, O95342, Q92887, O15438, O15439, Q03732, P08684, P10635, P11712, P0DTD1 |
| Iupac Name | 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| Prediction Hob | 1.0 |
| Target Id | NPT483, NPT51 |
| Xlogp | -0.9 |
| Molecular Formula | C8H11N3O3S |
| Prediction Swissadme | 1.0 |
| Inchi Key | JTEGQNOMFQHVDC-NKWVEPMBSA-N |
| Fcsp3 | 0.5 |
| Logs | -0.795 |
| Rotatable Bond Count | 2.0 |
| Logd | -1.632 |
| Compound Name | Lamivudine |
| Prediction Hob Swissadme | 1.0 |
| Exact Mass | 229.052 |
| Formal Charge | 0.0 |
| Monoisotopic Mass | 229.052 |
| Hydrogen Bond Acceptor Count | 4.0 |
| Molecular Weight | 229.26 |
| Covalent Unit Count | 1.0 |
| Total Atom Stereocenter Count | 2.0 |
| Total Bond Stereocenter Count | 0.0 |
| Esol | -1.8979182 |
| Inchi | InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1 |
| Smiles | C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N |
| Nring | 2.0 |
| Defined Bond Stereocenter Count | 0.0 |
- 1. Outgoing r'ship
FOUND_INto/from Citrus Bergamia (Plant) Rel Props:Source_db:npass_chem_all - 2. Outgoing r'ship
FOUND_INto/from Sophora Flavescens (Plant) Rel Props:Source_db:cmaup_ingredients;npass_chem_all - 3. Outgoing r'ship
FOUND_INto/from Strychnos Vanprukii (Plant) Rel Props:Source_db:cmaup_ingredients;npass_chem_all